777 related articles for article (PubMed ID: 26366797)
21. Vaginal lubricants and moisturizers: a review into use, efficacy, and safety.
Potter N; Panay N
Climacteric; 2021 Feb; 24(1):19-24. PubMed ID: 32990054
[TBL] [Abstract][Full Text] [Related]
22. The urogenital system and the menopause.
Calleja-Agius J; Brincat MP
Climacteric; 2015; 18 Suppl 1():18-22. PubMed ID: 26366796
[TBL] [Abstract][Full Text] [Related]
23. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.
Tan O; Bradshaw K; Carr BR
Menopause; 2012 Jan; 19(1):109-17. PubMed ID: 22011753
[TBL] [Abstract][Full Text] [Related]
24. Impact of vulvovaginal atrophy therapies on postmenopausal women's quality of life in the CRETA study measured by the Cervantes scale.
Palacios S; Sánchez-Borrego R; Suárez Álvarez B; Lugo Salcedo F; González Calvo AJ; Quijano Martín JJ; Cancelo MJ; Fasero M
Maturitas; 2023 Jun; 172():46-51. PubMed ID: 37099983
[TBL] [Abstract][Full Text] [Related]
25. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.
Simon JA; Goldstein I; Kim NN; Davis SR; Kellogg-Spadt S; Lowenstein L; Pinkerton JV; Stuenkel CA; Traish AM; Archer DF; Bachmann G; Goldstein AT; Nappi RE; Vignozzi L
Menopause; 2018 Jul; 25(7):837-847. PubMed ID: 29870471
[TBL] [Abstract][Full Text] [Related]
26. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
Portman D; Palacios S; Nappi RE; Mueck AO
Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.
Simon J; Portman D; Mabey RG;
Maturitas; 2014 Mar; 77(3):274-81. PubMed ID: 24411556
[TBL] [Abstract][Full Text] [Related]
28. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.
Portman DJ; Gass ML;
Maturitas; 2014 Nov; 79(3):349-54. PubMed ID: 25179577
[TBL] [Abstract][Full Text] [Related]
29. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
Bachmann GA; Komi JO;
Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Li N; Zhang Y
J Sex Med; 2014 Feb; 11(2):487-97. PubMed ID: 24251418
[TBL] [Abstract][Full Text] [Related]
31. Profile of ospemifene in the breast.
Berga SL
Reprod Sci; 2013 Oct; 20(10):1130-6. PubMed ID: 23945733
[TBL] [Abstract][Full Text] [Related]
32. Sequential treatment in vulvovaginal atrophy.
Palacios S
Climacteric; 2023 Aug; 26(4):292-295. PubMed ID: 37105219
[TBL] [Abstract][Full Text] [Related]
33. Ospemifene, vulvovaginal atrophy, and breast cancer.
Wurz GT; Soe LH; DeGregorio MW
Maturitas; 2013 Mar; 74(3):220-5. PubMed ID: 23332519
[TBL] [Abstract][Full Text] [Related]
34. Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy.
Crean-Tate KK; Faubion SS; Pederson HJ; Vencill JA; Batur P
Am J Obstet Gynecol; 2020 Feb; 222(2):103-113. PubMed ID: 31473229
[TBL] [Abstract][Full Text] [Related]
35. Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease.
Pérez-López FR; Phillips N; Vieira-Baptista P; Cohen-Sacher B; Fialho SCAV; Stockdale CK
Gynecol Endocrinol; 2021 Aug; 37(8):746-752. PubMed ID: 34169794
[TBL] [Abstract][Full Text] [Related]
36. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Gandhi J; Chen A; Dagur G; Suh Y; Smith N; Cali B; Khan SA
Am J Obstet Gynecol; 2016 Dec; 215(6):704-711. PubMed ID: 27472999
[TBL] [Abstract][Full Text] [Related]
37. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
Portman DJ; Bachmann GA; Simon JA;
Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
[TBL] [Abstract][Full Text] [Related]
38. Hormone Therapy and Other Treatments for Symptoms of Menopause.
Hill DA; Crider M; Hill SR
Am Fam Physician; 2016 Dec; 94(11):884-889. PubMed ID: 27929271
[TBL] [Abstract][Full Text] [Related]
39. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.
The NAMS 2020 GSM Position Statement Editorial Panel
Menopause; 2020 Sep; 27(9):976-992. PubMed ID: 32852449
[TBL] [Abstract][Full Text] [Related]
40. Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
Simon JA; Altomare C; Cort S; Jiang W; Pinkerton JV
J Womens Health (Larchmt); 2018 Jan; 27(1):14-23. PubMed ID: 29064335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
